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Tendon disease has been treated with multipotent mesenchymal stromal cells (MSCs) in the equine large-animal 
model with promising success. The aim of this study was to gain more insight into the fate and biodistribution of 
MSCs after local application into tendon lesions by long-term cell tracking in this large-animal model. Superficial 
digital flexor tendon lesions were induced in all limbs in six horses and injected with 10 × 106 Molday ION 
Rhodamine B™-labeled MSCs suspended in serum or serum alone. Follow-up was performed using low-field 
magnetic resonance imaging (MRI), flow cytometry, and histology. Cell tracking based on the hypointense arti-
facts induced by the superparamagnetic iron oxide (SPIO) labeling agent in MRI as well as based on Rhodamine 
B fluorescence was feasible. However, Prussian blue staining for assessment of histology was not entirely specific 
for SPIO. Labeled cells could be traced at their injection site by MRI as well as histology for the whole follow-up 
period of 24 weeks. Although the numbers of labeled cells within the injected tendon lesions decreased over time, 
part of the applied cells appeared to remain viable and integrated within the injured tissue. Furthermore, small 
numbers of labeled cells were identified in peripheral blood within the first 24 h after cell injection and could 
also be found until week 24 within the contralateral control tendon lesions that had been injected with serum. The 
present findings unveil details on MSC biodistribution and persistence after their local application, which are of 
clinical relevance with regard to MSC safety and mechanisms of action.
Key words: Tendon; Mesenchymal stromal cells (MSCs); Cell therapy; Cell tracking; Biodistribution; 
Superparamagnetic iron oxide (SPIO)
INTRODUCTION
Treatment of tendon disease is one of the highly prom-
ising options within the large field of potential clinical 
applications of multipotent mesenchymal stromal cells 
(MSCs). Studies performed in the equine species led to 
results that encourage further investigation (14,30,34). The 
horse is considered a natural model for tendon disease, as 
the etiopathogenesis of equine superficial digital flexor 
tendon and human Achilles tendon disease shows several 
similarities (26,28). Providing a basis for further transla-
tion of the therapeutic concept, the use of the equine large-
animal model for preclinical orthopedic research has been 
recommended in the guidelines issued by authorities such 
as the US Food and Drug Administration (FDA) and the 
European Medicines Agency (EMA) (18,37). With respect 
to using the horse not only for orthopedic but also for cell 
therapy research, we recently demonstrated a high level of 
analogy of equine and human MSCs (22), enabling the use 
of the horse in homologous models for cell therapies.
The approach previously used in the horse for cell 
therapy for tendon disease is based on the local, ultra-
sound-guided application of an MSC suspension. This 
was first published more than a decade ago (32) and has 
since then been shown to improve the tendon tissue archi-
tecture after injury (14,30,34). However, despite growing 
evidence regarding the efficacy, fundamental questions 
remain regarding the fate of the applied MSCs as well as 
their mechanism of action.
Previous studies that have been performed in order 
to track MSCs applied for treatment of tendon injuries 
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already give some insight into the fate and biodistribu-
tion of the cells. However, it is still difficult to assemble 
a comprehensive picture. In studies using the equine model 
and local application of MSCs transfected with green 
fluorescent protein (GFP), the cells could mainly (19,20) 
or exclusively (21) be found at their injection site by 
histological assessment. While giving good insight into 
MSC integration within the tissue microstructure, this 
technique is limited with regard to longitudinal cell track-
ing and detection of potential systemic MSC distribution 
in the large-animal model. Only low percentages such as 
<1% of the total injected MSCs could be found in tissue 
sections obtained 60 or 90 days after MSC application in 
this study, leading to the hypothesis of limited survival 
of the cells (21). Contrary to these results, in a similar 
study design using a sheep model and local application of 
red fluorescent protein (RFP)-transfected MSCs, persis-
tence of labeled MSCs was observed in the injected ten-
don lesions until 6 weeks after application (25). However, 
corresponding to the earlier study, no evidence of MSC 
migration and homing to distant locations was found in 
this study either (25).
A different approach with contrary advantages and 
disadvantages also being used in large-animal models is 
scintigraphic tracking of technetium-99-labeled MSCs 
(5,36). Here the major limitations are the short persis-
tence and detectability of cell labeling as well as the 
low spatial resolution. However, scintigraphic track-
ing can be used for monitoring cells in vivo and offers 
the best currently available opportunity to assess MSC 
biodistribution in large-animal species, at least over a 
short period of time. It also represents a possible tech-
nique for quantification of cell numbers, although the 
rapid loss of label remains an issue. So far, scintigra-
phy was mainly used to investigate alternative deliv-
ery routes for MSC treatment of tendon lesions, such 
as systemic intravenous injection or regional perfusion. 
Different studies consistently led to the result that direct 
intralesional injection of MSCs results in higher uptake 
within the lesion compared to regional perfusion (5,36), 
making this delivery route still appear most favorable. 
Nevertheless, regional perfusion as well as a single case 
of systemic intravenous injection also led to measurable 
uptake within the tendon lesion (5), suggesting homing 
of applied MSCs to injured regions, albeit with inad-
equate and inconsistent efficiency.
Adding to the question of potential homing, in a fur-
ther study using quantum dot labeling, MSCs could be 
detected histologically in locally injected tendon lesions, 
but not in contralateral control tendon lesions after 7 days 
(12). However, in the same study, distribution of labeled 
cells in the peripheral blood was observed by flow cytom-
etry, leading to the assumption they may have distributed 
to other parts of the body.
Taking these previous findings together, although 
there is evidence that local administration of MSCs is 
the method of choice for cell treatment of tendon disease, 
long-term intratendinous persistence and biodistribution 
of the MSCs are still not elucidated. Therefore, alterna-
tive techniques suitable for longitudinal cell tracking 
should be an area of focus.
Magnetic resonance imaging (MRI) may be a suit-
able tool for in vivo cell tracking studies. The use of 
modern high-field magnets in small animals results in 
high-resolution images revealing detailed information 
(2). Furthermore, albeit with lower resolution, MRI cell 
tracking is also feasible in large animals. MRI contrast 
agents for intracellular labeling such as superparamag-
netic iron oxide (SPIO) particles were shown to have no 
or low impact on in vitro cell properties (1,7,13,23) and 
persist in the cells for several weeks (7,15). SPIO par-
ticles lead to local magnetic field perturbations and can 
therefore be visualized as signal void susceptibility arti-
facts in MRI. Furthermore, SPIO-labeled cells stain posi-
tive for Prussian blue, potentially facilitating additional 
assessments by histology.
Recently, MRI has been described for in vivo cell 
tracking in induced tendon lesions in an ovine model 
(29). This study provided data on a limited follow-up time 
of 2 weeks but demonstrated that Prussian blue-positive 
histology staining was present within areas of the tendon 
lesions that corresponded well to the signal void areas in 
the MR images. Furthermore, using MSCs that had been 
transducted with green fluorescent protein and colabeled 
with SPIO, the presence of viable, labeled cells could be 
confirmed histologically (29).
We recently published the results of low-field MRI cell 
tracking over 8 weeks after treatment of tendon lesions 
in equine patients (6), demonstrating the feasibility of 
this technique in horses. The availability of an equine-
dedicated low-field MRI system offers the advantage 
that the animals do not require general anesthesia during 
the examinations, which facilitates monitoring at close 
intervals. In this study, tracking over 8 weeks provided 
new insight in terms of longer follow-up as well as SPIO-
artifact localization in naturally occurring tendon dis-
ease. However, because the animals were client-owned 
patients, no tissue samples could be harvested, impairing 
histological assessment. Adding to this patient study, a 
recent experimental pilot study in horses confirmed that 
MSC tracking in tendon lesions by low-field MRI is fea-
sible over a period of 9 weeks, while labeled cells could 
also be found histologically (19).
The aim of the current study was to perform longitudi-
nal cell tracking, combining in vivo MRI and histological 
assessment over a significant period of time, for which 
we chose a follow-up time of 24 weeks. Furthermore, we 
aimed to gain insight not only into the local distribution 
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of MSCs applied to induced tendon lesions but also into 
the potential systemic distribution and homing of MSCs 
to other injury sites. For this purpose, MSC labeling with 
SPIO particles conjugated to Rhodamine B was chosen to 
allow detection of cells by MRI and Prussian blue stain-
ing as well as fluorescence-based microscopy and flow 
cytometry, enabling comprehensive analysis of different 
types of samples.
MATERIALS AND METHODS
Animals and Induction of Tendon Lesions
Six healthy Standardbred horses (3–10 years; three 
females, three males) were used for this study. Horses 
were examined clinically and by ultrasonography as well 
as MRI of the metacarpal or metatarsal flexor tendons to 
rule out preexisting tendon disease prior to including the 
animals in the study. All procedures were approved by the 
local authority (Landesdirektion Leipzig, TV 34/13).
Tendon lesions were induced in the mid-metacarpal/ 
mid-metatarsal region of the superficial digital flexor ten-
dons in all four limbs (17) by combining a surgical proce-
dure with collagenase application. Horses were placed in 
lateral recumbency under general anesthesia, and the skin 
was prepared aseptically. Tendon lesions were induced by 
introducing an 11-gauge multiport bone marrow aspira-
tion needle through a 2-cm proximodistal skin incision. 
The needle was advanced within the tendon for a distance 
of 2 cm to proximal, then 0.4 ml of 4.8 mg/ml (250 IU 
per tendon lesion) collagenase I (Life Technologies 
GmbH, Darmstadt, Germany) solution was applied while 
slowly drawing the needle back. Subcutis and skin were 
closed by continuous suture and simple interrupted pat-
tern, respectively, and bandages were applied. Following 
the induction of tendon lesions, autologous subcutaneous 
adipose tissue was collected from the supragluteal region 
for isolation of autologous MSCs as described previ-
ously (8). All animals were administered flunixin meglu-
mine (Flunidol®; CP-Pharma Handelsgesellschaft mbH, 
Burgdorf, Germany) as a nonsteroidal anti-inflammatory 
drug [pre- and 10 h postsurgery: 1.1 mg/kg body weight 
(bwt) intravenously (IV); day 1 to day 4 postsurgery: 
0.55 mg/kg bwt per oral administration (PO) twice daily; 
day 5 to day 6 postsurgery: 0.55 mg/kg bwt PO once 
daily]. They were monitored at least three times daily for 
10 days using a pain score, which allowed standardized 
additional treatment if required. Single additional doses 
of pain medication (flunixin meglumine, 1.1 mg/kg bwt 
PO) were administered according to the standardized 
regime when an animal showed signs of discomfort or 
pain. The limbs were left bandaged for 14 days when the 
skin sutures were removed.
After surgery, horses were restricted to stall rest until 
2 weeks after MSC application. Thereafter, they were 
subjected to a standardized, gradually increasing exer-
cise program for tendon rehabilitation described previ-
ously (33).
MSC Isolation, Labeling, and Characterization
Mononuclear cells (MNCs) were isolated from the adi-
pose tissue collected after the induction of tendon lesions 
by collagenase I digestion as described previously (10). 
The plastic-adherent MSC fraction was expanded until 
passage 2.
MSCs were then labeled with Molday ION Rhodamine 
B™ (BioPAL Inc.™, Worcester, MA, USA) at an iron 
concentration of 25 µg Fe/ml culture medium at 37°C 
in humidified atmosphere for 20 h. Following labeling, 
MSCs were harvested, and 10 × 106 cells per tendon lesion 
to be treated were suspended in 1 ml of fresh autologous 
proband serum. Remaining labeled cells from each animal 
were used for the evaluation of labeling and trilineage dif-
ferentiation potential. For evaluation of labeling, MSCs 
were reseeded and incubated for 24 h for cell attach-
ment, and intracellular iron particles were stained with 
the Prussian Blue Reagent Pack (BioPAL Inc.™) accord-
ing to the manufacturer’s instructions. The percentage of 
Prussian blue-positive cells was assessed quantitatively 
by light microscopy in at least one 10× field of view per 
sample. In addition to that, the percentage of Rhodamine 
B-positive MSCs was assessed by flow cytometry as 
described below. Trilineage differentiation and subse-
quent stainings were performed as described previously 
(10,22). Briefly, Oil red O staining was performed to 
detect lipid droplets and von Kossa staining to detect 
mineralizations, and Alcian blue and Masson’s trichrome 
staining were used to demonstrate glysosaminoglycan 
and collagen deposition, respectively. Staining reagents 
were obtained from Carl Roth (Karlsruhe, Germany) and 
Sigma-Aldrich (Munich, Germany). Oil red O and von 
Kossa staining were combined with Prussian blue staining 
to detect remaining labeling agent after differentiation.
Furthermore, nonlabeled passage 2 cells from each ani-
mal were used for characterization of MSC surface antigens 
by flow cytometry. Immunostaining comprised staining of 
the putative positive markers CD29, CD 44, CD73, CD90, 
and CD105 and staining of the putative exclusion markers 
CD14, CD34, CD45, CD79a, and major histocompatibil-
ity complex (MHC) II. Primary antibodies were purchased 
from BioLegend (CD29; San Diego, CA, USA), Becton 
Dickinson (CD44; Franklin Lakes, NJ, USA), Abcam 
(CD73; Cambridge, UK), R&D Systems (CD90 and 
CD14; Minneapolis, MN, USA), Serotec (CD105, CD45, 
CD79a, and MHC II; Kidlington, UK), and Santa Cruz 
Biotechnology (CD34; Santa Cruz, CA, USA). All anti-
bodies and antigen subsets were chosen on the basis of pre-
vious studies, and staining as well as analysis procedures 
were performed accordingly (22,27).
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MSC Injection
Three weeks after induction of tendon lesions and 
adipose tissue collection, one randomly chosen fore-
limb and one randomly chosen hindlimb tendon lesion 
of each horse were injected locally with 10 × 106 labeled 
MSCs in 1 ml of autologous serum, while the respective 
contralateral tendon lesions were injected with 1 ml of 
serum only. The injections were performed in the stand-
ing sedated horses after perineural (ulnar nerve or lateral 
and medial plantar nerves) and local anesthesia using 
lidocain 2% (Bela-pharm GmbH & Co. KG, Vechta, 
Germany). All injections were performed by the same 
qualified veterinary surgeon unaware of the presence of 
MSCs in the respective syringes. In the weight-bearing 
limb, a 20-gauge needle was placed perpendicular to the 
tendon axis and advanced into the lesion. Intralesional 
placement of the needle was monitored by ultrasonogra-
phy using a 10-MHz linear transducer (LOGIQ 5 Expert; 
GE Healthcare, Munich, Germany) before MSCs or 
serum was applied. After the injection, the limbs were 
bandaged for 2 days. All animals were administered 
flunixin meglumine at the day of injection (1.1 mg/kg 
bwt IV) as well as the following day (0.55 mg/kg bwt 
PO).
Longitudinal Cell Tracking by MRI
MRI examinations were performed at regular inter-
vals in order to track the labeled MSCs longitudinally 
in vivo. T1-weighted and T2*-weighted gradient echo 
MRI series [slice thickness: 5 mm; gap: 1 mm; field of 
view: 171 mm × 171 mm; matrix: 256 × 256; repetition 
time (TR), T1w: 52 ms; TR, T2*w: 68 ms; echo time 
(TE), T1w: 8 ms; TE, T2*w: 13 ms; flip angle, T1w: 
50°; flip angle, T2*w: 25°] were acquired in a trans-
verse plane using an equine-dedicated low-field MRI 
system (EQ2; Hallmarq Veterinary Imaging, Guildford, 
Surrey, UK) for examinations in standing sedated horses 
as described previously (6). Examinations of all four 
limbs were performed directly before and after MSC 
application as well as 1, 2, and 3 weeks after MSC 
application. The MRI scans after MSC application were 
started immediately after the injection and completed 
within 4 h. After the hindlimb biopsies had been col-
lected at week 3, MRI examinations included the fore-
limbs only and were repeated 4, 6, 8, 12, and 24 weeks 
after MSC application.
MRI series were evaluated regarding the localization 
and dimension of the putatively iron oxide-induced hypoin-
tense artifacts over time using Synedra ViewPersonal, 
Version 3.4.0.2 (Synedra Information Technologies GmbH, 
Innsbruck, Austria). Localization was categorized as intra-
tendinous, predominantly intratendinous, equally intra-
tendinous and within surrounding tissue, predominantly 
within surrounding tissue, or within surrounding tissue. 
Artifact dimension was approximated by measuring its 
area in all consecutive images and multiplying the sum of 
artifact areas by 6 mm (5-mm slice thickness + 1-mm gap). 
Measurements were repeated three times, and mean values 
were used for further analysis.
Sample Collection for Flow Cytometry and Histology
Three weeks after cell application, 0.2-cm × 0.3-cm × 
2-cm tendon biopsies were recovered from the hindlimb 
maximum lesion and injection sites from all six horses 
under general anesthesia. Pain management was per-
formed as described above for the induction of ten-
don lesions. Biopsies were collected from the core of 
the tendon lesions via skin incision and using a scal-
pel to recover the sample piece under visual control. 
Tendon, subcutis, and skin were sutured, and the limbs 
were bandaged. Each hindlimb biopsy was divided into 
two parts. One part was fixed in 4% paraformaldehyde 
(PFA; Carl Roth) and subjected to histology. From the 
other part, cells were released by digestion in 5.6 mg/ml 
collagenase solution for 6 h at 37°C and subjected to 
flow cytometry.
Twenty-four weeks after cell application, all six horses 
were sacrificed, and the whole metacarpal regions of 
the forelimb tendons were collected. The tendons were 
divided into 2-cm-long sample pieces by transverse cut-
ting, the most proximal piece corresponding to the proxi-
mal aspect of the metacarpal region, and the most distal 
piece to the distal aspect of the metacarpal region. A cen-
tral part of each 2-cm piece was fixed in 4% PFA and 
subjected to histology.
Additional samples were collected from three of the 
animals (male; 5–9 years) to assess potential systemic 
distribution of MSCs as well as potential homing to 
other injury sites: 30 ml of peripheral blood samples 
was collected 1 h before and 1, 4, 8, 12 h, as well as 1, 
2, 3, 4, 5, and 6 days after MSC injection. MNCs in the 
blood samples were purified by density gradient centrif-
ugation at 327 × g (27) and assessed by flow cytometry. 
In addition to the tendon biopsies, at week 3 after cell 
application, 0.5-cm-diameter biopsies were collected 
from healthy and previously injured subcutaneous and 
muscle tissue. Previously injured tissue was taken from 
the (supra)gluteal region at the site where adipose tissue 
had been harvested, and healthy tissue was taken from 
the same (supra)gluteal region but in a distance of 30 
cm to the previous incision for adipose tissue harvest. 
Corresponding control biopsies were collected from 
two different horses, which had not been included in the 
study procedures before. These two animals had never 
received labeled MSCs but had undergone the same 
surgical procedure for adipose tissue harvest the same 
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period of time ago. The biopsies were fixed in 4% PFA 
and subjected to histology.
Flow Cytometry
Freshly labeled MSCs as well as MNCs recovered from 
the peripheral blood samples were stained with Fixable 
eFluor 780® (eBioscience, Frankfurt a.m., Germany) for 
exclusion of dead cells in flow cytometry. Stained labeled 
and unstained nonlabeled control cells were fixed with 
2% PFA. Rhodamine B fluorescence of live cells was 
analyzed using a FACSCanto II (Becton Dickinson). For 
blood samples, a minimum of 5 × 106 events was recorded. 
Rhodamine B fluorescence of cells released from the ten-
don biopsies was analyzed without previous cell fixation 
using a FACSAria III™ (Becton Dickinson). Data analy-
sis was performed with FlowJo software version 10.0.7 
(FlowJo LLC, Ashland, OR, USA).
Histology
All biopsies obtained at week 3 as well as all sam-
ples obtained from the whole forelimb tendons at week 
24 were processed into 3-µm paraffin sections. Two 
nonadjacent sections from each sample were subjected 
to Prussian blue staining with nuclear fast red (Sigma-
Aldrich) counterstaining, while two corresponding sec-
tions were subjected to 4¢,6-diamidino-2-phenylindole 
(DAPI; Carl Roth) counterstaining of nuclei. Whole slide 
images of each section were obtained in a slide scanner 
(Pannoramic SCAN; 3DHISTECH, Budapest, Hungary) 
and were used for the evaluation of histology. The pres-
ence of fibroblast-like structures displaying Prussian 
blue staining was quantified by two blinded, indepen-
dent observers. Furthermore, corresponding DAPI-stained 
sections were evaluated with regard to the presence of 
Rhodamine B-positive cells. Representative sections of 
MSC- and serum-injected tendon lesions were addition-
ally examined with an inverted confocal laser scanning 
microscope TCS SP5 (Leica Microsystems, Wetzlar, 
Germany). To avoid cross talk in excitation of 375 and 
561 nm in multiple-stained compounds, a sequential scan-
ning mode was executed. Images were analyzed with the 
software Leica Application Suite Advanced Fluorescence 
2.6.0 (Leica Microsystems) and Adobe Photoshop CS 
(Adobe Systems, Munich, Germany).
Statistical Analysis
Data are presented as median and interquartile 
range (IQR). Statistical analysis was performed using 
SPSS Statistics 22 software (IBM Deutschland GmbH, 
Ehningen, Germany). As not all data were evenly distrib-
uted, for comparisons between paired groups, Wilcoxon 
tests were performed. Differences were considered sig-
nificant at p < 0.05.
RESULTS
Tendon Lesions and Surgeries
The technique for tendon lesion induction led to repro-
ducible core lesions that had largely the same appearance 
as natural equine tendon lesions in ultrasonography, MRI, 
and histology (unpublished data). The surgeries for ten-
don lesion induction and biopsy sampling were gener-
ally tolerated well, although the latter caused obvious 
additional injury. During the first days after surgery, the 
animals showed mild to moderate signs of pain, which 
were manageable with the flunixin meglumine treatment 
specified above. During the rest of the study period, the 
animals did not show signs of pain or discomfort related 
to the surgeries, except for initial mild lameness, which 
decreased and disappeared after the first few weeks.
MSC Characterization and Labeling
The isolated cells were positive for CD29 [61.9% 
(IQR: 55.4%)], CD44 [IQR: 90.6% (IQR: 14.1%)], CD90 
[6.5% (IQR: 29.6%)], and CD105 [25.6% (IQR: 15.3%)] 
and showed no or less than 2.0% expression of CD73, 
CD14, CD34, CD45, CD79a, and MHC II.
Labeling with Molday ION Rhodamine B was con-
firmed to be highly efficient. Evaluation by light micros-
copy showed that 100.0% (IQR: 2.7%) of MSCs were 
Prussian blue positive (Fig. 1). Flow cytometry led to cor-
responding results, with 99.8% (IQR: 0.4%) Rhodamine 
B-positive cells.
Furthermore, labeled MSCs from all animals showed 
trilineage differentiation potential, showing intracellular 
lipid droplets after adipogenic induction, extracellular 
mineralized matrix after osteogenic induction, as well 
as glycosaminoglycan and collagen deposition (data not 
shown) after chondrogenic pellet culture (Fig. 1).
Persistence of labeling particles during MSC differ-
entiation was distinct in the chondrogenic pellet cultures, 
which all displayed marked brownish accumulations in 
close proximity to the cell nuclei after the incubation time 
of 21 days. In contrast, Prussian blue-positive staining 
could only be observed in few single cells after 7 days of 
monolayer culture and adipogenic differentiation, and no 
Prussian blue-positive cells were found after osteogenic 
induction in monolayer culture for 21 days (Fig. 1).
Longitudinal MRI Cell Tracking
After the injection of labeled MSCs, hypointense arti-
facts were visible in T1- and T2*-weighted MR images. 
These artifacts remained present in the MSC-injected 
limbs of all animals until week 24, while no such artifacts 
had been visible before the injection of MSCs (Fig. 2). 
Furthermore, no distinct artifacts were observed in the 
contralateral limbs.
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The volume of the artifacts present within the limbs 
gradually decreased over time and was significantly 
lower at week 12 and week 24 compared to the earlier 
examinations in both T1- and T2*-weighted sequences 
(p < 0.05) (Fig. 2). Furthermore, while showing a similar 
decreasing trend, the volume of the hindlimb artifacts was 
lower compared to the forelimbs, which was significant 
in T1-weighted images at weeks 1, 2, and 3 (p < 0.05).
After cell application, artifacts were localized intra-
tendineously as well as within the surrounding tissue in 
11 out of 12 limbs. In the remaining limb, the artifact 
was found only in the surrounding tissue. In one further 
limb, artifact localization shifted from intratendineous to 
the surrounding tissue during the first week of follow-up. 
However, in all other cases, the artifacts constantly 
remained intratendineous, and their localization even 
became more central within the lesion over time in 3 out 
of 12 limbs.
Labeled Cells in Peripheral Blood
Flow cytometry could detect small numbers of Rhoda-
mine B-positive cells within the peripheral blood-derived 
mononuclear cells (PB-MNCs), indicating distribution 
of labeled MSCs with the circulating blood. Numbers of 
detectable Rhodamine B-positive cells varied between 
animals, but the highest cell numbers over time were con-
sistently found within the first 24 h after MSC injection. 
Maximum Rhodamine B-positive cell counts ranged from 
9,079 per 106 cells at 8 h postinjection in one animal to 513 
and 304 per 106 cells at 12 h postinjection in the other two 
animals. After reaching these respective maxima, the num-
bers of Rhodamine B-positive cells decreased. In the latter 
two animals, no more labeled cells were detected after 2 
days, while in the first animal, cell numbers ranging from 
234 to 569 per 106 cells remained detectable until day 6.
Labeled Cells in Tissue Samples
Prussian blue-positive staining could be observed in tis-
sue sections of the tendon injury site prepared at week 3 
as well as week 24 after MSC application. The staining 
partly occurred as blue specks of undefined shapes but was 
mostly associated with cell nuclei and displayed defined, 
fibroblast-like shapes. This was evident not only in the 
tendons injected with labeled MSCs but also in the con-
tralateral tendon lesions (Fig. 3) as well as in the injured 
subcutaneous and muscle tissue. However, importantly, 
although in lower quantities, similar occurrence of Prussian 
blue staining was found in the control injured subcutaneous 
Figure 1. MSC differentiation and labeling. Representative images of trilineage differentiation of labeled MSCs. (A) Oil red O 
staining of lipid droplets after adipogenic induction, the inset displaying one of the few cells still staining positive for Prussian 
blue after adipogenic differentiation. (B) von Kossa staining of mineralizations after osteogenic induction. (C) Alcian blue staining 
of glycosaminoglycans after chondrogenic pellet culture; note the brownish iron oxide accumulations in areas of high cellularity. 
(D) Prussian blue staining of the intracellular iron oxide particles in undifferentiated, freshly labeled MSCs. Scale bars: 200 µm, unless 
marked otherwise.
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and muscle tissue samples of the animals that had never 
received labeled MSCs (Fig. 4). In contrast, in sections of 
healthy tendon recovered distal or proximal to the injury 
site or sections of healthy subcutaneous and muscle tissue, 
Prussian blue staining was negative.
Prussian blue-positive fibroblast-like structures within 
the tendon samples were present in higher numbers at 
week 3 compared to week 24 after MSC application. 
Furthermore, while the numbers obtained at week 3 were 
similar in injected and contralateral tendons, at week 24 
higher numbers were found in the tendon lesions injected 
with labeled MSCs compared to the contralateral lesions 
(Fig. 3). However, these differences were not significant.
More specific assessment on the basis of Rhodamine 
B labeling revealed that Rhodamine B-positive cells were 
actually present in the MSC-injected as well as in the 
contralateral tendon lesions in all animals. However, 
the presence of equal numbers of labeled cells in both 
MSC-injected and contralateral tendon lesions at week 
3, as suggested by Prussian blue staining, could not be 
confirmed, neither microscopically nor by flow cytom-
etry. Rather, flow cytometry at week 3 revealed that in 
the MSC-injected lesion, 2.5% (IQR: 3.1%) of total cells 
recovered from the maximum lesion site were Rhodamine 
B positive, while in the contralateral lesion lower num-
bers of cells [0.5% (IQR: 0.5%)] were positive (Fig. 5). 
However, the cell numbers found in the MSC-injected 
lesion were variable, as demonstrated by the compara-
tively high IQR; thus, the difference between MSC-
injected and contralateral lesion was not significant.
Figure 2. MRI cell tracking. Representative images of T1- and T2*-weighted gradient echo MRI sequences before and at different 
time points after cell application, and boxplot displaying the artifact volume over time. Left upper image: the superficial digital flexor 
tendon with its hyperintense lesion is indicated by the white line. Arrows point at the hypointense artifact putatively induced by the 
iron oxide-labeled MSCs. Note that the artifact becomes smaller over time, as also demonstrated by the decreasing artifact volume. 
Boxplot: circles and rhombs display outliers, and stars indicate significant differences compared to the earlier time points (p < 0.05).
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Prussian blue- as well as Rhodamine B-positive cells 
were predominantly localized in groups within the enlarged 
endo- and peritenon, often in close proximity to blood ves-
sels, or aligned between nonmature tendon fibers. Further-
more, additional Prussian blue staining with undefined 
shapes was observed in most samples obtained from tendon 
lesions, which was partly reflected by an occasional occur-
rence of single Rhodamine B-positive particles (Fig. 3).
DISCUSSION
In this study, we performed the first long-term longitu-
dinal cell tracking in a large-animal model of tendon dis-
ease, aiming to gain insight into local persistence as well 
as potential systemic distribution of locally applied MSCs. 
We found evidence that part of the labeled cells remained at 
the local injection site for the whole follow-up period of 24 
weeks. However, our results also suggest that a limited and 
variable number of locally injected cells is distributed via 
the blood circulation and relocates to other injury sites.
Finding reliable techniques for tracking of trans-
planted cells is still challenging, and it is inevitable to 
deal with their limitations. We aimed to combine different 
approaches to overcome part of these limitations but still 
faced some issues that should be considered.
MRI is an advantageous technique for long-term 
tracking as it is noninvasive and can therefore be used to 
obtain valuable information over time. At the same time, 
MRI cell tracking has some obvious limitations. First, the 
Figure 4. Prussian blue staining in scar tissue. Muscle and subcutaneos scar tissue obtained 6 weeks after injury (A) displaying exten-
sive Prussian blue staining (arrows) in an animal that had received an intratendineous injection of iron oxide-labeled MSCs 3 weeks 
before the biopsy was taken and (B) displaying moderate Prussian blue staining in an animal that had never received labeled MSCs. 
Scale bars: 100 µm. The rectangles in (A1) and (B1) mark the areas displayed in higher magnification in (A2) and (B2).
FACING PAGE
Figure 3. Histology of tendon lesions. Representative images of tendon lesion histology obtained 24 weeks after MSC applica-
tion and boxplot displaying the numbers of Prussian blue-positive, fibroblast-like structures in tissue sections obtained from the 
maximum lesion site at week 3 and week 24 as well as mean values of all tissue sections obtained from each tendon at week 24. 
(A) Prussian blue staining potentially indicating presence of iron oxide particles or hemorrhage. (B) Rhodamine B fluorescence 
(red) of iron oxide particles and DAPI staining of nuclei (blue). (A1, B1) Tendon lesions injected with serum only. (A2, B2) Tendon 
lesions injected with labeled MSCs (MSC inj.). Black arrows point at accumalations of Prussian blue staining, partly displaying 
fibroblast-like shapes; white arrows point at Rhodamine B-positive particles associated with cell nuclei, which were considered as 
labeled MSCs; gray arrows point at isolated fluorescent particles. Black scale bars: 100 µm, white scale bars: 20 µm. Circle and 
rhomb in the boxplot show outliers.
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SPIO-induced hypointense artifacts observed in MRI do 
not always show a specific appearance and can therefore 
be confused with other hypointense tissue areas. This can 
be of particular importance for cell tracking in tendons, as 
their healthy fibers naturally display hypointense signal in 
standard MRI sequences. In our previous work, we aimed 
to validate the specificity of the cell tracking technique 
by comparing blinded subjective evaluation and quantita-
tive assessment. While recognition of artifacts by blinded 
observers was surprisingly good, the results still under-
lined the importance of signal intensity quantification (6). 
In the current study, the latter was confirmed to be con-
stantly low (data not shown), and results were addition-
ally validated using the magic angle technique for MRI 
(unpublished data) (9), indicating a reliable identification 
of SPIO-artifacts and artifact volume.
However, even if artifacts can be correctly related to the 
presence of SPIO particles, MRI does not provide infor-
mation on whether these SPIO particles are consistently 
labeling the cells in question. Moreover, when interpret-
ing artifact localization, it should be acknowledged that 
its dimensions depend on the amount of iron. Therefore, it 
remains possible that at high SPIO concentrations, the area 
covered by artifact exceeds the exact localization of labeled 
cells (6). The latter is likely to occur during the first days 
after cell labeling only (6), but eventually both issues can 
only be clarified on the basis of corresponding histology.
Furthermore, MRI is not suitable to investigate systemic 
distribution of labeled cells. At least for large animals, this 
is due to the fact that scans need to be restricted to certain 
areas of the body. Moreover, this is also due to the limited 
sensitivity when it comes to distribution and dilution of 
labeled cells. Regarding the latter, 100,000 MSCs labeled 
at the same concentration as used in this study can be distin-
guished from agar gel by low-field MRI, but lower concen-
trations cannot be identified reliably (6). Correspondingly, 
using 3-T high-field MRI, 10,000 SPIO-labeled MSCs 
were still visible in agar gel, but differences in MRI signal 
were less pronounced compared to 100,000 or more cells 
(29). Therefore, it can be assumed that only accumulations 
of roughly 100,000 labeled cells or more can be visualized 
under in vivo conditions. For more sensitive cell detection, 
further techniques need to be applied.
Despite its limitations, MRI documented the distribu-
tion of artifact within the lesion and surrounding tissue 
over time. Artifact was constantly found within the tendon 
lesion, but distribution in the peritendineous tissue was also 
evident, suggesting partial leakage of MSCs. While it could 
be speculated that this was due to the artificial character of 
the tendon lesions, as the peritendineum was incised during 
their induction, we observed similar artifact distribution in 
patients with natural tendon core lesions (6). Furthermore, 
this finding is in accordance with a recent study (19) show-
ing that cell application has yet to be optimized.
Histology, while also being limited to specific tissue 
areas, gives insight into tissue microstructure and allows 
to identify single cells. Here the major challenge is the 
appropriate labeling and staining. Prussian blue staining 
Figure 5. Flow cytometry of tendon lesions. Representative histogram displaying the number of events versus Rhodamine B fluo-
rescence intensity. The light gray line represents unstained control cells, and the dark gray line represents the cells recovered from a 
tendon lesion 3 weeks after injection of labeled MSCs. The boxplot displays the Rhodamine B-positive percentage of cells recovered 
from the tendon lesions injected with labeled MSCs (MSC inj.) and the contralateral tendons injected with serum only. Circle and 
rhomb show outliers.
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offers the advantage that it allows the assessment by light 
microscopy, facilitating an evaluation of its localization 
within the tissue microstructure. Staining appears to be 
used as a gold standard for the identification of SPIO par-
ticles in tissue sections (29,38) and was discussed as being 
suitable to confirm that MRI artifacts correspond to SPIO 
rather than hemorrhage (29). However, in the context of 
MRI cell tracking, it is often neglected that Prussian blue 
staining is not specific for the iron oxide particles used 
for cell labeling. Prussian blue staining occurs in the pres-
ence of Fe(III) and is traditionally used for the identifica-
tion of red blood cell degradation and siderophages. In 
forensic medicine, it is helpful to determine wound age 
(16). Consequently, Prussian blue staining could occur at 
previously injured tissue regions irrespective of the pres-
ence of SPIO particles. Therefore, in the current study, 
control samples of injured tissue were prepared to gain 
more insight into the specificity of the staining for SPIO 
detection. In fact, the control injured tissue also displayed 
positive staining, although not as extensive as found in the 
animals treated with SPIO-labeled MSCs. Based on that, 
while it still appears reasonable that Prussian blue stain-
ing of cellular structures is correlated with the presence of 
labeled cells, this staining alone does not ultimately prove 
the presence of labeled cells.
In the current study, evaluation of the simultaneous 
Rhodamine B labeling could confirm the presence of 
labeled cells within the tendon lesions. However, as was 
to be expected considering that part of the Prussian blue 
staining was due to previous hemorrhage, Rhodamine 
B-labeled cells were found in lower quantities than 
Prussian blue staining in corresponding slides, especially 
at week 3. This finding corresponds to the previous study 
performed in sheep using simultaneous green fluorescent 
protein transfection and SPIO labeling of MSCs. Here 
particularly 2 weeks after cell application, less GFP stain-
ing was observed not only compared to week 1 but also 
compared to corresponding Prussian blue-stained sections 
(29). The authors interpreted this finding to be due to the 
occurrence of free SPIO particles, which is a possibility 
that should not be dismissed in the current study either.
While transfected GFP most reliably identifies the 
actual transplanted cells, its expression is not related to 
the SPIO particles; thus, using this technique cannot finally 
explore their fate. Particularly, discrepancies between 
GFP expression and Prussian blue staining could merely 
be related to the presence of blood cell degradation prod-
ucts staining positive for the latter. In the current study, 
SPIO particles were directly conjugated to Rhodamine B 
and only rarely occurred without associated nuclei. This 
suggests that even after 24 weeks the occurrence of free 
SPIO particles is not a major issue. Nevertheless, it is still 
possible that SPIO particles are not located in the cyto-
plasm of the initially labeled MSCs but in macrophages 
that have phagocytosed free particles. On the basis of 
immunohistochemical costaining of macrophages in pre-
liminary experiments as well as on the general morpho-
logical differences of macrophages and MSCs, we believe 
that macrophages do not make a major contribution to the 
labeled cell population. However, simultaneous detection 
of GFP and SPIO labeling would be required to prove 
this assumption.
As the detection of Rhodamine B-positive cells proved 
to be more specific than the detection of Prussian blue-
positive cells, it would have provided valuable informa-
tion to quantify the occurrence of labeled cells based 
on their fluorescence instead of Prussian blue staining. 
However, partially occurring autofluorescence of collagen 
fibers and erythrocytes in the histological sections ham-
pered a clear distinction of all labeled cells. Therefore, 
to prevent false-positive results, we restricted the assess-
ment of Rhodamine B-positive cells in histological sec-
tions to a descriptive evaluation of the cells that could 
clearly be recognized. However, flow cytometry of cells 
released from corresponding tissue samples at week 3 
supported the subjective evaluation of tissue sections and 
demonstrated higher median numbers of labeled cells in 
the MSC-injected lesions and lower median numbers of 
labeled cells in the contralateral lesions.
The fact that small numbers of labeled cells could be 
found at the contralateral lesion sites that had not received 
MSC injections is not astonishing, given that MSCs are 
also found in the peripheral blood within the first hours 
after their application. This was not only observed in 
the current study but also corresponds to the findings in 
previous work (12). In both studies, it was also evident 
that numbers of labeled cells within the peripheral blood 
decreased within 7 days after their application. This leads 
to the hypothesis that the cells mainly enter the blood cir-
culation around the time of injection, which can likely 
be due to damage of small blood vessels by the injection 
cannula. Correspondingly, results of a scintigraphic study 
showed that more than half of the cell label initially found 
at the injection site is lost during the first 24 h (36). Once 
having entered the blood circulation, MSCs are likely to 
home to other injury sites mediated by chemokines and 
integrins, which has repeatedly been described and inves-
tigated (35). However, our finding of labeled cells relocat-
ing to other injury sites after local application in tendon 
lesions is new compared to previous studies (12,21,25).
While interesting, the clinical relevance of this find-
ing is not finally clear, as local injection still appears to 
be the most effective delivery route for treatment of ten-
don lesions (36). Nevertheless, it should be considered 
that MSC distribution and persistence are not exclu-
sively local when evaluating the safety of the therapy. 
Furthermore, the finding is of relevance for the design 
of studies on MSC treatment efficacy. In order to limit 
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the number of animals required, it is current practice to 
use lesions induced in the contralateral limb of the same 
animal as negative controls (11,14,30). However, some 
of the MSCs injected into one limb could relocate to the 
contralateral limb, which then does not represent a com-
pletely reliable negative control, although the effect of a 
few relocated cells is presumably low.
Most importantly, the current findings strongly sug-
gest that MSCs remain at the site of tendon injury after 
local application for a period of at least 24 weeks. This 
assumption is supported by the constantly low signal of 
artifacts found at the injection site, but more importantly, 
labeled cells could be identified in the corresponding 
histological sections. The number of cells concentrated 
within the tendon lesion decreased over time, as indicated 
by the decreasing volume of the artifacts in MRI as well 
as observed in the histological sections. Nevertheless, 
given that at week 24 several cells could still be identified 
in separate tissue sections, each representing only a very 
small percentage of the whole tendon lesion, the results 
suggest that part of the locally applied MSCs remain via-
ble and integrate within the injured tissue. However, it 
should not be neglected that there is also cell distribution 
to distant locations as well as partial leakage of injected 
cells into peritendineous tissues. Future studies still need 
to reveal the exact percentage of cells surviving at the 
lesion site after an optimized application procedure.
It should also be acknowledged that cell-labeling 
agents, including SPIO, can have side effects (3,4), which 
can hamper the observation of physiological processes in 
labeled cells and their environment. Moreover, the dis-
ease model used could have an impact on MSC behavior, 
particularly on cell survival and homing. The two most 
frequently used techniques for tendon lesion induction 
in large animals are collagenase application (24), which 
can induce massive inflammation, and surgical disrup-
tion of tendon tissue (31), which physically destroys large 
amounts of tendon fibers. The model used in the current 
study combined both techniques, using a low dose of col-
lagenase and very limited tissue disruption, aiming to 
minimize the disadvantages of both approaches. In addi-
tion to that, it remains to be considered that tendon heal-
ing and MSC distribution in fore- and hindlimbs may not 
be identical (17). However, MRI findings in the current 
study were very similar to those in our previous study in 
equine patients with natural forelimb tendon lesions.
Therefore, it could be assumed that the model used 
largely reflects the natural condition; thus, the present 
findings could be of high practical relevance. The results 
of the current study appear to be relevant with respect 
to the potential mechanisms of action of MSCs in ten-
don regeneration, as persistence of the cells over a long 
period of time would potentially allow them to continu-
ously influence local regenerative processes.
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